Zoetis Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Zoetis Inc. (ZTS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $32.64 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-06
- Zoetis Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $32.64, a 18.83% decline year-over-year.
- Zoetis Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $40.21, a 21.16% decline year-over-year.
- Zoetis Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $51.00, a 17.08% increase year-over-year.
- Zoetis Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $43.56, a 14.82% decline year-over-year.
- Zoetis Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $40.22, a 20.78% decline from fiscal 2024.
- Zoetis Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $50.77, a 16.55% increase from fiscal 2023.
- Zoetis Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $43.56, a 14.81% decline from fiscal 2022.
- Zoetis Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $51.13, a 35.23% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $32.64 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $32.64 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $40.22 10-K · filed 2026-02-12 | |||
| 2025-09-30 | $40.22 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | $40.22 10-Q · filed 2025-08-05 | |||
| 2025-03-31 | $40.21 10-Q · filed 2025-05-06 | |||
| 2024-12-31 | $50.77 10-K · filed 2026-02-12 | |||
| 2024-09-30 | $50.90 10-Q · filed 2024-11-04 | |||
| 2024-06-30 | $50.98 10-Q · filed 2024-08-06 | |||
| 2024-03-31 | $51.00 10-Q · filed 2024-05-02 | |||
| 2023-12-31 | $43.56 10-K · filed 2026-02-12 | |||
| 2023-09-30 | $43.56 10-Q · filed 2023-11-02 | |||
| 2023-06-30 | $43.56 10-Q · filed 2023-08-08 | |||
| 2023-03-31 | $43.56 10-Q · filed 2023-05-04 | |||
| 2022-12-31 | $51.13 10-K · filed 2025-02-13 | |||
| 2022-09-30 | $51.13 10-Q · filed 2022-11-03 | |||
| 2022-06-30 | $51.13 10-Q · filed 2022-08-04 | |||
| 2022-03-31 | $51.14 10-Q · filed 2022-05-05 | |||
| 2021-12-31 | $37.81 10-K · filed 2024-02-13 | |||
| 2021-09-30 | $37.81 10-Q · filed 2021-11-04 | |||
| 2021-06-30 | $37.81 10-Q · filed 2021-08-05 | |||
| 2021-03-31 | $37.82 10-Q · filed 2021-05-06 | |||
| 2020-12-31 | $34.22 10-K · filed 2023-02-14 | |||
| 2020-09-30 | $33.83 10-Q · filed 2020-11-05 | |||
| 2020-06-30 | $33.83 10-Q · filed 2020-08-06 | |||
| 2020-03-31 | $33.92 10-Q · filed 2020-05-06 | |||
| 2019-12-31 | $21.84 10-K · filed 2022-02-15 | |||
| 2019-09-30 | $21.82 10-Q · filed 2019-11-07 | |||
| 2019-06-30 | $21.82 10-Q · filed 2019-08-06 | |||
| 2019-03-31 | $21.78 10-Q · filed 2019-05-02 | |||
| 2018-12-31 | $20.30 10-K · filed 2021-02-16 | |||
| 2018-09-30 | $20.30 10-Q · filed 2018-11-01 | |||
| 2018-06-30 | $20.30 10-Q · filed 2018-08-02 | |||
| 2018-03-31 | $20.29 10-Q · filed 2018-05-02 | |||
| 2017-12-31 | $14.31 10-K · filed 2020-02-13 | |||
| 2017-10-01 | $14.31 10-Q · filed 2017-11-02 | |||
| 2017-07-02 | $14.30 10-Q · filed 2017-08-08 | |||
| 2017-04-02 | $14.30 10-Q · filed 2017-05-04 | |||
| 2016-12-31 | $11.34 10-K · filed 2019-02-14 | |||
| 2016-10-02 | $11.29 10-Q · filed 2016-11-03 | |||
| 2016-07-03 | $11.21 10-Q · filed 2016-08-05 | |||
| 2016-04-03 | $11.19 10-Q · filed 2016-05-06 | |||
| 2015-12-31 | $11.70 10-K · filed 2018-02-15 | |||
| 2015-09-27 | $11.70 10-Q · filed 2015-11-05 | |||
| 2015-06-28 | $11.69 10-Q · filed 2015-08-06 | |||
| 2015-03-29 | $11.72 10-Q · filed 2015-05-07 | |||
| 2014-12-31 | $8.01 10-K · filed 2017-02-16 | |||
| 2014-09-28 | $8.01 10-Q · filed 2014-11-10 | |||
| 2014-06-29 | $8.00 10-Q · filed 2014-08-12 | |||
| 2014-03-30 | $8.01 10-Q · filed 2014-05-13 | |||
| 2013-12-31 | $7.05 10-K · filed 2015-02-27 | |||
| 2013-09-29 | $7.05 10-Q · filed 2013-11-13 | |||
| 2013-06-30 | $7.02 10-Q · filed 2013-08-14 | |||
| 2013-03-31 | $7.01 10-Q · filed 2013-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |